Prevents bronchospasm with reversible obstructive airway disease. ANDA 209959, held by Cipla. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 209959 (Albuterol Sulfate), held by Cipla, was first approved by FDA on Apr 8, 2020, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol sulfate inhalation aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 8, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.09MG BASE/INH · aerosol, metered;inhalation | Albuterol Sulfate | Rx |
| Nov 21, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Oct 28, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 4, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 8, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters